Merck Essentially Options A Pipeline In Collaboration With NGM

The big pharma gets one preclinical candidate for cardio-metabolic indications now and options to virtually everything else in the biotech’s pipeline. NGM receives $94 million up front, $250 million in R&D funding over five years and a $106 million equity investment.

Merck & Co. Inc.’s wide-ranging collaboration with NGM Biopharmaceuticals Inc., announced Feb. 23, leaves the privately held cardio-metabolic disease specialist independent, but gives Merck access to nearly all of the unpartnered assets in NGM’s pipeline – and those to come.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America